Profluent & Lilly: $2.25B AI Genetic Medicine Partnership
Eli Lilly and Profluent Forge $2.25 Billion AI Alliance for Next-Generation Genetic Medicine In a move that signals a paradigm shift in biotechnology, pharmaceutical giant Eli Lilly has announced a massive strategic investment to redefine the boundaries of gene editing. The company has entered a strategic partnership with Profluent to develop AI-designed recombinases, a technology … Read more